Diacerein-mediated inhibition of IL-6/IL-6R signaling induces apoptotic effects on breast cancer

Oncogene

Volumn 35, Issue 30, 2016, Pages 3965-3975

  Bharti, R ^a   Dey, G ^a   Ojha, P K ^b   Rajput, S ^a   Jaganathan, S K ^c   Sen, R ^a   Mandal, M ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY   (India)

^b JADAVPUR UNIVERSITY   (India)

^c UNIVERSITI TEKNOLOGI MALAYSIA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; DIACEREIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; STAT3 PROTEIN; ANTHRAQUINONE DERIVATIVE; ANTIINFLAMMATORY AGENT; STAT3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL PROLIFERATION; COMPETITIVE BINDING ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG BINDING SITE; DRUG PROTEIN BINDING; FEMALE; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTHERMAL TITRATION CALORIMETRY; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; TUNEL ASSAY; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; METABOLISM; NUCLEOCYTOPLASMIC TRANSPORT; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTHRAQUINONES; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; INTERLEUKIN-6; PHOSPHORYLATION; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955288756     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.466     Document Type: Article

References (52)

1. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006; 5: 689-702.
2. Palumbo A, Facon T, Sonneveld P, Blade J, Offidani M, Gay F et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008; 111: 3968-3977.
3. Pooja S, Chaudhary P, Nayak LV, Rajender S, Saini KS, Deol D et al. Polymorphic variations in IL-1beta, IL-6 and IL-10 genes, their circulating serum levels and breast cancer risk in Indian women. Cytokine 2012; 60: 122-128.
4. Sachdev JC, Jahanzeb M. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer. Clin Breast Cancer 2012; 12: 19-29.
5. Culig Z. Cytokine disbalance in common human cancers. Biochim Biophys Acta 2011; 1813: 308-314.
6. Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression. Physiology 2010; 25: 85-101.
7. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30: 1073-1081.
8. Silver JS, Hunter CA. gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukocyte Biol 2010; 88: 1145-1156.
9. Gibson RM, Schiemann WP, Prichard LB, Reno JM, Ericsson LH, Nathanson NM. Phosphorylation of human gp130 at Ser-782 adjacent to the di-leucine internalization motif-Effects on expression and signaling. J Biol Chem 2000; 275: 22574-22582.
10. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011; 121: 3375-3383.
11. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Blood 2001; 98: 639a.
12. Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH, Steiner H et al. The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 2007; 26: 2822-2832.
13. Lu ZM, Xu SC. ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life 2006; 58: 621-631.
14. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cel Sci 2004; 117: 1281-1283.
15. Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and Phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 2003; 9: 594-600.
16. Puthier D, Derenne S, Barille S, Moreau P, Harousseau JL, Bataille R et al. Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br J Haematol 1999; 107: 392-395.
17. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009; 15: 91-102.
18. Guo YQ, Xu F, Lu TH, Duan ZF, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012; 38: 904-910.
19. Berishaj M, Gao SP, Ahmed S, Leslie K, Al-Ahmadie H, Gerald WL et al. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Br Cancer Res 2007; 9: R32.
20. Shariat SF, Chromecki TF, Hoefer J, Barbieri CE, Scherr DS, Karakiewicz PI et al. Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner. J Urol 2011; 186: 2107-2114.
21. Rokavec M, Oner MG, Li H, Jackstadt R, Jiang L, Lodygin D et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest 2014; 124: 1853-1867.
22. Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 2001; 61: 8851-8858.
23. Rose-John S. GP130 stimulation and the maintenance of stem cells. Trends Biotechnol 2002; 20: 417-419.
24. Calisto KL, Camacho AC, Mittestainer FC, Carvalho BM, Guadagnini D, Carvalheira JB et al. Diacerhein attenuates the inflammatory response and improves survival in a model of severe sepsis. Crit Care 2012; 16: R158.
25. Gadotti VM, Martins DF, Pinto HF, Oliveira G, Kaster MP, Quintao NLM et al. Diacerein decreases visceral pain through inhibition of glutamatergic neurotransmission and cytokine signaling in mice. Pharmacol Biochem Behav 2012; 102: 549-554.
26. Varghese JN, Moritz RL, Lou MZ, Van Donkelaar A, Ji H, Ivancic N et al. Structure of the extracellular domains of the human interleukin-6 receptor alpha-chain. Proc Natl Acad Sci USA 2002; 99: 15959-15964.
27. Michaud-Levesque J, Bousquet-Gagnon N, Beliveau R. Quercetin abrogates IL-6/STAT3 signaling and inhibits glioblastoma cell line growth and migration. Exp Cell Res 2012; 318: 925-935.
28. Ataie-Kachoie P, Pourgholami MH, Morris DL. Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer. Cytokine Growth Factor Rev 2013; 24: 163-173.
29. Liu Y, Li PK, Li CL, Lin JY. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J Biol Chem 2010; 285: 27429-27439.
30. Kamran MZ, Patil P, Gude RP. Role of STAT3 in cancer metastasis and translational advances. Biomed Res Int 2013; 2013: 421821.
31. Yosifov DY, Reufsteck C, Konstantinov SM, Berger MR. Interleukin-6, osteopontin and Raf/MEK/ERK signaling modulate the sensitivity of human myeloma cells to alkylphosphocholines. Leukemia Res 2012; 36: 764-772.
32. Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res 2007; 13: 6469-6478.
33. Liu Y, Liu AG, Li HM, Li CL, Lin JY. Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells. Cancer Prev Res 2011; 4: 1296-1305.
34. Brinkmann K, Kashkar H. Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies Cell Death Dis 2014; 5: e1098.
35. Johnson C, Han Y, Hughart N, McCarra J, Alpini G, Meng F. Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer 2012; 1: 58-70.
36. Ara T, DeClerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 2010; 46: 1223-1231.
37. Liu YX, Law BK, Luesch H, Apratoxin A. Reversibly inhibits the secretory pathway by preventing cotranslational translocation. Mol Pharmacol 2009; 76: 91-104.
38. Chakravarti N, Myers JN, Aggarwal BB. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). Int J Cancer 2006; 119: 1268-1275.
39. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003; 171: 3863-3871.
40. Plotnikov A, Zehorai E, Procaccia S, Seger R. The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim Biophys Acta 2011; 1813: 1619-1633.
41. Andersen JL, Schroder TJ, Christensen S, Strandbygard D, Pallesen LT, Garcia-Alai MM et al. Identification of the first small-molecule ligand of the neuronal receptor sortilin and structure determination of the receptor-ligand complex. Acta Crystallogr D Biol Crystallogr 2014; 70: 451-460.
42. Mahata D, Mandal SM, Bharti R, Gupta VK, Mandal M, Nag A et al. Self-assembled cardanol azo derivatives as antifungal agent with chitin-binding ability. Int J Biol Macromol 2014.;69: 5-11.
43. Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher PB, Mandal M. ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells. J Cel Physiol 2011; 226: 375-384.
44. Das S, Dey KK, Bharti R, MaitiChoudhury S, Maiti S, Mandal M. PKI 166 induced redox signalling and apoptosis through activation of p53, MAP kinase and caspase pathway in epidermoid carcinoma. J Exp Ther Oncol 2012; 10: 139-153.
45. Rajput S, BNP Kumar, Dey KK, Pal oI, Parekh A, Mandal M. Molecular targeting of Akt by thymoquinone promotes G(1) arrest through translation inhibition of cyclin D1 and induces apoptosis in breast cancer cells. Life Sci 2013; 93: 783-790.
46. Venkatesan P, Puvvada N, Dash R, Kumar BNP, Sarkar D, Azab B et al. The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer. Biomaterials 2011; 32: 3794-3806.
47. Rajput S, Kumar BNP, Sarkar S, Das S, Azab B, Santhekadur PK et al. Targeted apoptotic effects of thymoquinone and tamoxifen on XIAP mediated Akt regulation in breast cancer. PLoS One 2013; 8: e61342.
48. Venkatesan SK, Shukla AK, Dubey VK. Molecular docking studies of selected tricyclic and quinone derivatives on trypanothione reductase of leishmania infantum. J Comput Chem 2010; 31: 2463-2475.
49. Su JL, Lai KP, Chen CA, Yang CY, Chen PS, Chang CC et al. A novel peptide specifically binding to interleukin-6 receptor (gp80) inhibits angiogenesis and tumor growth. Cancer Res 2005; 65: 4827-4835.
50. Mandal M, Adam L, Mendelsohn J, Kumar R. Nuclear targeting of Bax during apoptosis in human colorectal cancer cells. Oncogene 1998; 17: 999-1007.
51. Sethi G, Chatterjee S, Rajendran P, Li F, Shanmugam MK, Wong KF et al. Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo. Mol Cancer 2014; 13: 66.
52. Dey G, Bharti R, Dhanarajan G, Das S, Dey KK, Kumar BN et al. Marine lipopeptide Iturin A inhibits Akt mediated GSK3beta and FoxO3a signaling and triggers apoptosis in breast cancer. Sci Rep 2015; 5: 10316.